Glofitamab is a bispecific antibody that targets both CD20, a protein found on the surface of B cells (a type of white blood cell involved in many blood cancers), and CD3, a protein on T cells (another type of immune cell). By binding to both CD20 and CD3, glofitamab brings T cells into close proximity with B cells, including cancerous B cells.

This dual binding activates the T cells, causing them to attack and destroy the CD20-expressing B cells. This mechanism helps the immune system target and kill lymphoma cells. In clinical studies, glofitamab has shown anti-tumor activity in patients with diffuse large B-cell lymphoma (DLBCL) and large B-cell lymphoma (LBCL) arising from follicular lymphoma.

The medication can cause a rapid decrease in B cell counts and a temporary increase in cytokines (immune signaling molecules), which is part of its intended effect but also contributes to some of its side effects.

Glofitamab

Common brand names

Approved use in